- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
GigaPath AI Model May Predict Cancer Mutations, Tumor Mutation Burden in Lung, Other Cancers
September 16th 2024, 8:30pm
AI models like GigaPath may pave the way for other predictive models in cancer, as it deciphers diagnoses and mutations in a more granular method.
AMG 193 Shows Preliminary Clinical Activity in MTAP-Deleted Solid Tumors
September 16th 2024, 8:15pm
AMG 193, an MTA-cooperative PRMT5 inhibitor, demonstrated responses and an acceptable safety profile across patients with MTAP-deleted solid tumors.
Nonoperative Management Maintains DFRS, Promotes Organ Preservation in pMMR Rectal Cancer
September 16th 2024, 7:24pm
In the NO-CUT trial, 97% of patients with pMMR locally advanced rectal cancer sustained distant relapse-free survival with nonoperative management.
Inavolisib Demonstrates Safety, Disease Control in PIK3CA-Mutated Solid Tumors
September 16th 2024, 7:21pm
Inavolisib demonstrated a favorable safety profile and generated disease control in patients with tumors harboring PIK3CA mutations.
Dr Popat on OS Outcomes With Amivantamab Plus Chemotherapy in EGFR-Mutated, Advanced NSCLC
September 16th 2024, 6:15pm
Sanjay Popat, BSc, MBBS, FRCP, PhD, discusses OS data with amivantamab plus chemotherapy in EGFR-mutated, advanced NSCLC after progression on osimertinib.
Darolutamide Plus ADT Improves rPFS in mHSPC
September 16th 2024, 5:38pm
Darolutamide plus ADT shows PFS benefit without docetaxel in metastatic hormone-sensitive prostate cancer.
Abemaciclib/ET Combo Improves Responses vs Chemo in Aggressive HR+/HER2– Breast Cancer
September 16th 2024, 4:54pm
Frontline abemaciclib plus ET demonstrated a superior ORR vs chemotherapy in HR+/HER2– advanced breast cancer with aggressive disease characteristics.
Multivariate Analysis Provides Additional Insight on Efficacy of 177Lu-Dotatate in GEP-NETs
September 16th 2024, 4:54pm
Lutetium Lu 177 dotatate shows consistent efficacy over high-dose octreotide in advanced GEP-NETs, according to data from the NETTER-2 trial.
Durvalumab/Tremelimumab Sustains OS Benefit in Unresectable HCC
September 16th 2024, 4:51pm
Tremelimumab plus durvalumab sustained an overall survival improvement in unresectable hepatocellular carcinoma.
Adjuvant Ribociclib Sustains DFS, DDFS Benefit in HR+/HER2– Breast Cancer
September 16th 2024, 4:00pm
Adding ribociclib to a NSAI in the adjuvant setting prolonged invasive and distant disease-free survival in HR-positive, HER2-negative early breast cancer.
Neoadjuvant TAR-200/Cetrelimab Combo Shows Activity in Muscle-Invasive Bladder Cancer
September 16th 2024, 2:38pm
Neoadjuvant TAR-200 plus cetrelimab elicited responses and was safe in muscle-invasive bladder cancer.
Pooled TRUST-I and TRUST-II Data Affirm Taletrectinib Benefits for Advanced ROS1+ NSCLC
September 16th 2024, 6:28am
Taletrectinib elicited high and durable overall response rates with favorable tolerability in patients with advanced ROS1-positive NSCLC.
Addition of Perioperative Durvalumab to Neoadjuvant Chemo Generates Survival Benefits in Cisplatin-Eligible MIBC
September 15th 2024, 7:52pm
NIAGARA was the first phase 3 study to evaluate perioperative immunotherapy plus neoadjuvant chemotherapy in cisplatin-eligible muscle-invasive bladder cancer.
T-DXd Delays Time to Deterioration in Functioning, Pain in HR+, HER2-Low and -Ultralow Metastatic Breast Cancer
September 15th 2024, 7:29pm
T-DXd improved time to deterioration for pain and other subscores, with no decline in overall QOL in HER2 low/ultralow breast cancer.
Perioperative Nivolumab Shows EFS Benefit vs Placebo in Resectable NSCLC
September 15th 2024, 6:22pm
Perioperative nivolumab extended event-free survival vs placebo in patients with resectable non–small cell lung cancer.
Early Switch Therapy to Atezolizumab After Vemurafenib/Cobimetinib Run-in Improves OS in BRAF V600–Positive Melanoma
September 15th 2024, 6:10pm
Early switch therapy to atezolizumab after run-in with vemurafenib plus cobimetinib led to improved 4- and 5-month OS rates in BRAF V600–positive melanoma.
RP1 Plus Nivolumab Demonstrates Durable Antitumor Activity in Advanced Melanoma
September 15th 2024, 5:13pm
RP1 plus nivolumab offers durable responses and a favorable safety profile for patients with melanoma after progression on anti–PD-1 therapy.
Dr Choueiri on Lessons Learned from the TiNivo-2 Study in Metastatic RCC
September 15th 2024, 4:55pm
Toni Choueiri, MD, discusses findings with tivozanib plus nivolumab in metastatic RCC after progression on an immune checkpoint inhibitor.
TORL-1-23 Is Tolerable, Active in Heavily Pretreated CLDN6+ Advanced Ovarian Cancer, Other Solid Tumors
September 15th 2024, 4:40pm
TORL-1-23 was safe and active in heavily pretreated, Claudin-6–positive advanced solid tumors, including platinum-resistant ovarian cancer.
Dr Secord on Mirvetuximab Soravtansine in Platinum-Sensitive, FRα-High Ovarian Cancer
September 15th 2024, 4:35pm
Angeles A. Secord, MD, MHSc, discusses the PICCOLO trial of mirvetuximab soravtansine in recurrent, platinum-sensitive, FRα-high ovarian cancer.